Home / 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study – Discussant
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study – Discussant
2023-03-11
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
